Converting potent indeno[1,2-b]indole inhibitors of protein kinase CK2 into selective inhibitors of the breast cancer resistance protein ABCG2.
暂无分享,去创建一个
Joachim Jose | Jean Guillon | A. di Pietro | Evelyn Winter | G. Jabor Gozzi | J. Jose | N. Pinaud | Attilio Di Pietro | M. Le Borgne | G. Valdameri | Glaucio Valdameri | Evelyn Winter | Z. Bouaziz | Marc Le Borgne | Zouhair Bouaziz | Nathalia Daflon-Yunes | Christelle Marminon | Andre Bollacke | Noël Pinaud | Silvia M Cadena | Gustavo Jabor Gozzi | Dagmar Aichele | Abdelhamid Nacereddine | Waël Zeinyeh | Aline Lacoudre | J. Guillon | S. M. Cadena | Nathalia Daflon-Yunes | Christelle Marminon | A. Bollacke | D. Aichele | Abdelhamid Nacereddine | Wael Zeinyeh | Aline Lacoudre | S. Cadena
[1] N. Taylor,et al. Total synthesis of isoprekinamycin: structural evidence for enhanced diazonium ion character and growth inhibitory activity toward cancer cells. , 2007, Organic letters.
[2] L. Pinna,et al. Structural and functional analysis of the flexible regions of the catalytic α-subunit of protein kinase CK2. , 2012, Journal of structural biology.
[3] G. Szakács,et al. Structure-activity relationships of chromone derivatives toward the mechanism of interaction with and inhibition of breast cancer resistance protein ABCG2. , 2013, Journal of medicinal chemistry.
[4] S. Bates,et al. Comparison of ATP-Binding Cassette Transporter Interactions with the Tyrosine Kinase Inhibitors Imatinib, Nilotinib, and Dasatinib , 2010, Drug Metabolism and Disposition.
[5] F. Totzke,et al. Indeno[1,2-b]indole derivatives as a novel class of potent human protein kinase CK2 inhibitors. , 2012, Bioorganic & medicinal chemistry.
[6] R. Prudent,et al. Structure-based discovery of small molecules targeting different surfaces of protein-kinase CK2. , 2010, Biochimica et biophysica acta.
[7] P. Houghton,et al. Imatinib Mesylate Is a Potent Inhibitor of the ABCG2 (BCRP) Transporter and Reverses Resistance to Topotecan and SN-38 in Vitro , 2004, Cancer Research.
[8] F. Zhou,et al. Casein kinase 2 inhibition attenuates androgen receptor function and cell proliferation in prostate cancer cells , 2012, The Prostate.
[9] Fu-Yuan Tsai,et al. In Silico Prediction of Inhibition of Promiscuous Breast Cancer Resistance Protein (BCRP/ABCG2) , 2014, PloS one.
[10] I. Catalá,et al. Frequent expression of the multi‐drug resistance‐associated protein BCRP/MXR/ABCP/ABCG2 in human tumours detected by the BXP‐21 monoclonal antibody in paraffin‐embedded material , 2002, The Journal of pathology.
[11] N. Oleinick,et al. Staurosporine-induced death of MCF-7 human breast cancer cells: a distinction between caspase-3-dependent steps of apoptosis and the critical lethal lesions. , 2003, Experimental cell research.
[12] E. P. Kennedy,et al. The enzymatic phosphorylation of proteins. , 1954, The Journal of biological chemistry.
[13] Ulf Norinder,et al. A Global Drug Inhibition Pattern for the Human ATP-Binding Cassette Transporter Breast Cancer Resistance Protein (ABCG2) , 2007, Journal of Pharmacology and Experimental Therapeutics.
[14] A. di Pietro,et al. ABCG2: recent discovery of potent and highly selective inhibitors. , 2013, Future medicinal chemistry.
[15] Christin Müller,et al. Potent and selective inhibitors of breast cancer resistance protein (ABCG2) derived from the p-glycoprotein (ABCB1) modulator tariquidar. , 2009, Journal of medicinal chemistry.
[16] S. Bates,et al. Linsitinib (OSI-906) antagonizes ATP-binding cassette subfamily G member 2 and subfamily C member 10-mediated drug resistance. , 2014, The international journal of biochemistry & cell biology.
[17] T. Pawson,et al. Identification of a Novel Protein Interaction Motif in the Regulatory Subunit of Casein Kinase 2 , 2013, Molecular and Cellular Biology.
[18] M. Ychou,et al. Sorafenib Overcomes Irinotecan Resistance in Colorectal Cancer by Inhibiting the ABCG2 Drug-Efflux Pump , 2013, Molecular Cancer Therapeutics.
[19] O. Issinger,et al. Isolation and characterization of recombinant human casein kinase II subunits α and β from bacteria , 1991 .
[20] O. Issinger,et al. First structure of protein kinase CK2 catalytic subunit with an effective CK2β-competitive ligand. , 2013, ACS chemical biology.
[21] L. Galluzzi,et al. Erlotinib antagonizes ABC transporters in acute myeloid leukemia , 2012, Cell cycle.
[22] G. Kéri,et al. High-affinity interaction of tyrosine kinase inhibitors with the ABCG2 multidrug transporter. , 2004, Molecular pharmacology.
[23] S H Kaufmann,et al. The HER tyrosine kinase inhibitor CI1033 enhances cytotoxicity of 7-ethyl-10-hydroxycamptothecin and topotecan by inhibiting breast cancer resistance protein-mediated drug efflux. , 2001, Cancer research.
[24] M. Sainsbury,et al. The Coupling Reactions of 3-Acylindoles and Proof of Structure of the Palladium (II) Acetane Mediated Cyclisation Reaction Product of 3-Benzoyl-1-methylindole , 1983 .
[25] P. L. Ee,et al. Dimethoxyaurones: Potent inhibitors of ABCG2 (breast cancer resistance protein). , 2008, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[26] C. Götz,et al. A CE‐based assay for human protein kinase CK2 activity measurement and inhibitor screening , 2010, Electrophoresis.
[27] I. Bilbao-Meseguer,et al. Drug interactions with sunitinib , 2015, Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners.
[28] S. Bates,et al. Inhibition of ABCG2-mediated transport by protein kinase inhibitors with a bisindolylmaleimide or indolocarbazole structure , 2007, Molecular Cancer Therapeutics.
[29] K. Matsuo,et al. Synthesis of murrayaquinone-A. , 1994, Chemical & pharmaceutical bulletin.
[30] A. Buschauer,et al. Solid phase synthesis of tariquidar-related modulators of ABC transporters preferring breast cancer resistance protein (ABCG2). , 2011, Bioorganic & medicinal chemistry letters.
[31] J. Dagorn,et al. A Review of Kinases Implicated in Pancreatic Cancer , 2010, Pancreatology.
[32] F. Totzke,et al. Novel indeno[1,2-b]indoloquinones as inhibitors of the human protein kinase CK2 with antiproliferative activity towards a broad panel of cancer cell lines. , 2012, Biochemical and biophysical research communications.
[33] H. G. Richey,et al. Sulfamides and sulfonamides as polar aprotic solvents , 1987 .
[34] Veerababurao Kavala,et al. An Easy Access to Carbazolones and 2,3-Disubstituted Indoles , 2011 .
[35] D. Birnbaum,et al. Protein kinase CK2α subunit over-expression correlates with metastatic risk in breast carcinomas: quantitative immunohistochemistry in tissue microarrays. , 2011, European journal of cancer.
[36] G. Reiss,et al. Partially Saturated Indeno[1,2-b]indole Derivatives via Deoxygenationof Heterocyclic α-Hydroxy-N,O-hemiaminals , 2009 .
[37] J. Jose,et al. Synthesis and biological evaluation of novel substituted pyrrolo[1,2-a]quinoxaline derivatives as inhibitors of the human protein kinase CK2. , 2013, European journal of medicinal chemistry.
[38] Joachim Jose,et al. Synthesis and Biological Evaluation of 3-(Substituted-benzylidene)-1,3-dihydro-indolin Derivatives as Human Protein Kinase CK2 and p60c-Src Tyrosine Kinase Inhibitors , 2007 .
[39] G. Sheldrick. A short history of SHELX. , 2008, Acta crystallographica. Section A, Foundations of crystallography.
[40] M. Hawkins,et al. Bryostatin-I—An Antineoplastic Treasure from the Deep? , 2002, Cancer biology & therapy.
[41] G. K. Gray,et al. Therapeutic CK2 inhibition attenuates diverse prosurvival signaling cascades and decreases cell viability in human breast cancer cells , 2014, Oncotarget.
[42] J. Schellens,et al. Potent and specific inhibition of the breast cancer resistance protein multidrug transporter in vitro and in mouse intestine by a novel analogue of fumitremorgin C. , 2002, Molecular cancer therapeutics.
[43] A. Goffeau,et al. Protein kinase C effectors bind to multidrug ABC transporters and inhibit their activity. , 2001, Biochemistry.
[44] Timothy J. Mitchison,et al. A chemical method for fast and sensitive detection of DNA synthesis in vivo , 2008, Proceedings of the National Academy of Sciences.
[45] D. Richardson,et al. Molecular Pharmacology of ABCG2 and Its Role in Chemoresistance , 2013, Molecular Pharmacology.
[46] G. Szakács,et al. Interaction of the EGFR inhibitors gefitinib, vandetanib, pelitinib and neratinib with the ABCG2 multidrug transporter: implications for the emergence and reversal of cancer drug resistance. , 2012, Biochemical pharmacology.
[47] T. Kinoshita,et al. Crystal structure of human CK2α at 1.06 Å resolution , 2013, Journal of synchrotron radiation.
[48] H. Willard,et al. Recent developments in the detection of deoxyribonucleic acid synthesis by 33258 Hoechst fluorescence. , 1975, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.
[49] M. Bredel,et al. Targeting Protein Kinase CK2 Suppresses Prosurvival Signaling Pathways and Growth of Glioblastoma , 2013, Clinical Cancer Research.
[50] Min Zhao,et al. Inhibition of CK2 enhances UV-triggered apoptotic cell death in lung cancer cell lines. , 2013, Oncology reports.
[51] T. Mosmann. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. , 1983, Journal of immunological methods.
[52] L. Cesaro,et al. Aberrant signalling by protein kinase CK2 in imatinib‐resistant chronic myeloid leukaemia cells: Biochemical evidence and therapeutic perspectives , 2013, Molecular oncology.
[53] Y. Sugimoto,et al. Gefitinib reverses breast cancer resistance protein-mediated drug resistance. , 2004, Molecular cancer therapeutics.